The Bacterial Type III Secretion System as a Target for Developing New Antibiotics

View/ Open
Issue Date
2014-12-17Author
McShan, Andrew C.
De Guzman, Roberto N.
Publisher
wiley
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
© 2015 John Wiley & Sons A/S
Metadata
Show full item recordAbstract
Antibiotic resistance in pathogens requires new targets for developing novel antibacterials. The bacterial type III secretion system (T3SS) is an attractive target for developing antibacterials as it is essential in the pathogenesis of many Gram-negative bacteria. The T3SS consists of structural proteins, effectors and chaperones. Over 20 different structural proteins assemble into a complex nanoinjector that punctures a hole on the eukaryotic cell membrane to allow the delivery of effectors directly into the host cell cytoplasm. Defects in the assembly and function of the T3SS render bacteria non-infective. Two major classes of small molecules, salicylidene acylhydrazides and thiazolidinones, have been shown to inhibit multiple genera of bacteria through the T3SS. Many additional chemically and structurally diverse classes of small molecule inhibitors of the T3SS have been identified as well. While specific targets within the T3SS of a few inhibitors have been suggested, the vast majority of specific protein targets within the T3SS remain to be identified or characterized. Other T3SS inhibitors include polymers, proteins and polypeptides mimics. In addition, T3SS activity is regulated by its interaction with biologically relevant molecules, such as bile salts and sterols, which could serve as scaffolds for drug design.
Collections
Citation
McShan, A. C. and De Guzman, R. N. (2015), The Bacterial Type III Secretion System as a Target for Developing New Antibiotics. Chem Biol Drug Des, 85: 30–42. doi:10.1111/cbdd.12422
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.